Results 111 to 120 of about 15,465 (199)

IFN‐γ‐Associated Signaling Networks in Interstitial Lung Disease Associated With Sjögren's Disease

Immunity, Inflammation and Disease, Volume 14, Issue 10, October 2026.
ABSTRACT Background Sjögren's disease (SD) is a chronic systemic autoimmune disorder that can affect multiple organ systems. Interstitial lung disease (ILD) is a clinically significant pulmonary manifestation of SD and is associated with impaired quality of life and increased mortality.
Qianqian Chen, Yuhan Li, Yiming Chen, Yuhua Su, Xiaodong Wang, Chunxiao Guan   +5 more
wiley   +1 more source

Baricitinib Mitigates Methotrexate-Induced Liver Fibrosis Model via YAP Pathway

Background and Objectives: Liver fibrosis, a chronic process caused by various pathogenic factors, including drug toxicity, metabolic disorders, and chronic inflammation, is associated with liver-related mortality rates worldwide. It has been established
Ozkan Simsek, Erbas, Oytun, Ciftci, Bertug Bekir, Simsek, Ozkan, Mumin Alper Erdogan, Mehmet Ulusan, Erdogan, Mumin Alper, Dogan, Zafer, Bertug Bekir Ciftci, Ulusan, Mehmet, ATALAN, GÜLTEKİN, Gultekin Atalan, Oytun Erbas, Zafer Dogan   +13 more
core   +1 more source

Hippo Pathway–YAP/TAZ Signaling: Molecular Mechanisms, Biological Function, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 10, October 2026.
The Hippo–YAP/TAZ–TEAD pathway integrates mechanical and biochemical cues to govern organ growth, regeneration, cancer, and fibrosis. This review dissects pathway physiology, TEAD structural pharmacology and ligandable pockets, and therapeutic strategies spanning palmitoylation‐pocket inhibitors, PROTAC degraders, and gene/RNA therapies, highlighting ...
Xiaodan Qu, Zhan‐you Wang
wiley   +1 more source

Therapeutic Response of Alopecia Areata-Associated Nail Changes to Baricitinib

Case Reports in Dermatological Medicine
Nail changes are seen in some individuals with alopecia areata, with the most common variants including pitting and trachyonychia. The nail findings are presumed to be due to the same lymphocytic infiltration seen in hair bulbs in individuals with AA ...
Ashley Wittmer, Katherine De Jong, Lauren Bolish, Lindsey Finklea   +3 more
doaj   +1 more source

Direct Effects of the Janus Kinase Inhibitor Baricitinib on Sensory Neurons [PDF]

Therapeutically, the Janus kinase (Jak) 1/Jak2 inhibitor baricitinib reduces the pathology of rheumatoid arthritis and may also reduce pain. Here, we investigated whether baricitinib directly affects joint nociceptors.
Enrique Vazquez, Eitner, Annett, Annett Eitner, Schaible, Hans-Georg, Frank Richter, König, Christian, Gabriel Natura, Christian König, Richter, Frank, Hans-Georg Schaible, Natura, Gabriel, Vazquez, Enrique   +11 more
core   +1 more source

Acute Pustular Facial Eruption in a 5‐Year‐Old Boy

Pediatric Dermatology, EarlyView.
Naia Oillarburu, Magalie Coco‐Viloin, Emilie Tournier, Juliette Mazereeuw‐Hautier, Maella Severino‐Freire   +4 more
wiley   +1 more source

Ischemic Stroke and Traumatic Brain Injury: Epidemiology, Molecular Pathways, and Emerging Therapies

MedComm, Volume 7, Issue 10, October 2026.
Schematic overview of secondary brain injury after ischemic stroke and traumatic brain injury. Both conditions trigger endothelial cell dysfunction, pericyte contraction, and upregulated AQP4 expression in astrocytic end‐feet, leading to blood–brain barrier disruption.
Mengzhao Feng, Qi Qin, Fang Wang, Kaiyuan Zhang, Zhihua Li, Junlei Chang, Min Yu, Fuyou Guo   +7 more
wiley   +1 more source

Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate‐to‐Severe Atopic Dermatitis

Allergy, Volume 81, Issue 10, Page 3599-3607, October 2026.
Atopic dermatitis (AD) is characterized by microbial dysbiosis. This study aimed to evaluate the effects of abrocitinib, a JAK1‐selective inhibitor, on the skin microbiome and its potential associations with clinical outcomes in patients with AD. Abrocitinib treatment was associated with increased skin microbial diversity and decreased Staphylococcus ...
Madeline Kim, Ester Del Duca, Joel Correa Da Rosa, Juliana Pulsinelli, Yeriel Estrada, Dan Xu, Gary Chan, Allshine Chen, Erman Güler, Karen Page, Emma Guttman‐Yassky   +10 more
wiley   +1 more source

PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs

RMD Open
Objective To compare the effectiveness of a strategy administering baricitinib versus one using TNF-inhibitors (TNFi) in patients with rheumatoid arthritis (RA) after conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) failure in a ...
Mart van de Laar, Tim Jansen, A Willemze, Y P M Goekoop-Ruiterman, Reinhard Bos, Eric-Jan Kroot, Celine J van de Laar, Martijn A H Oude Voshaar, Peter ten Klooster, Danyta I Tedjo, Grada A Versteeg   +10 more
doaj   +1 more source

Emerging Paediatric Uses of Dupilumab Beyond Approvals

Clinical &Experimental Allergy, Volume 56, Issue 10, Page 1162-1176, October 2026.
Dupilumab, through IL‐4Rα blockade, shows promising efficacy beyond approved indications in paediatric diseases driven by T2 inflammation. Emerging evidence—mainly from small studies—supports improvements in disease severity and quality of life, highlighting its potential as a targeted, steroid‐sparing therapy while underscoring the need for ...
Simone Foti Randazzese, Anna Calamita, Diletta D'Angelo, Alessia Marseglia, Esther Mesa Lombardero, Sara Pedersoli, Micol Tedeschi, Mara De Amici, Sara Manti, Valeria Brazzelli, Amelia Licari, Gian Luigi Marseglia   +11 more
wiley   +1 more source